Boehringer Ingelheim Venture Fund logo

Boehringer Ingelheim Venture Fund

Europe, Rheinland-Pfalz, Germany, Ingelheim Am Rhein

Description

Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.

Investor Profile

Boehringer Ingelheim Venture Fund has made 91 investments, with 5 in the past 12 months and 49% as lead.

Stage Focus

  • Series A (44%)
  • Series B (25%)
  • Seed (18%)
  • Series C (8%)
  • Series Unknown (4%)
  • Pre Seed (1%)

Country Focus

  • Germany (29%)
  • United States (24%)
  • Switzerland (11%)
  • Belgium (9%)
  • France (8%)
  • United Kingdom (5%)
  • China (3%)
  • Sweden (2%)
  • Israel (2%)
  • Spain (2%)

Industry Focus

  • Biotechnology
  • Therapeutics
  • Health Care
  • Medical
  • Life Science
  • Oncology
  • Medical Device
  • Biopharma
  • Pharmaceutical
  • Artificial Intelligence (Ai)
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Boehringer Ingelheim Venture Fund frequently co-invest with?

Wellington Partners
Europe, Bayern, Germany, Munich
Co-Investments: 7
Gimv
Europe, Antwerpen, Belgium, Antwerpen
Co-Investments: 5
BioMedPartners
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 8
HTGF | High-Tech Gruenderfonds
Europe, Nordrhein-Westfalen, Germany, Bonn
Co-Investments: 18
Forbion Capital Partners
Europe, Noord-Holland, The Netherlands, Naarden
Co-Investments: 5
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 7
Kurma Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 6
EQT Life Sciences
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 5
Idinvest Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 5
PMV
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 5

Which angels does Boehringer Ingelheim Venture Fund often collaborate with?

Shared Deals: 1
LD
North America, Virginia, United States, Richmond
Shared Deals: 1

What are some of recent deals done by Boehringer Ingelheim Venture Fund?

Brainomix

Oxford, Oxfordshire, United Kingdom

Brainomix specializes in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions

Artificial Intelligence (AI)BiotechnologyMachine LearningMedicalMedical DevicePrecision MedicineSoftware
Series CMar 18, 2025
Amount Raised: $18,163,655
Refoxy Pharma

Berlin, Berlin, Germany

Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity.

ManufacturingPharmaceuticalTherapeutics
SeedDec 4, 2024
Amount Raised: $9,566,159
Aignostics

Berlin, Berlin, Germany

Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research.

Artificial Intelligence (AI)Health CareHealth DiagnosticsMachine LearningSoftware
Series BOct 29, 2024
Amount Raised: $34,000,000
Shengbao Bio

Shenzhen, Guangdong, China

Shengbao Bio is committed to the development of novel live bacterial medications, leveraging gene circuits and precise regulation of gene.

BiotechnologyMedicalPharmaceutical
Series AJul 26, 2024
HepaRegeniX

Ulm, Baden-Wurttemberg, Germany

HepaRegeniX is developing drugs for treating acute and chronic liver diseases.

BiotechnologyHealth CareLife ScienceTherapeutics
Series CJul 10, 2024
Amount Raised: $16,228,567
Asgard Therapeutics

Lund, Skane Lan, Sweden

Asgard Therapeutics is a Biotechnology Company.

BiotechnologyTherapeutics
Series AMar 14, 2024
Amount Raised: $32,648,548
Glox Therapeutics

Glasgow, Glasgow City, United Kingdom

Glox Therapeutics creates precision antibiotics through the use of engineered protein bacteriocins.

BiotechnologyProduct Research
SeedNov 14, 2023
Amount Raised: $5,372,300
Actym Therapeutics, Inc.

Berkeley, California, United States

Actym Therapeutics is a biotech company that focuses on the discovery and development of novel immuno-oncology therapies to treat cancer.

BiotechnologyMedicalMedical DeviceOncology
Series AOct 18, 2023
Amount Raised: $25,500,000
smartbax

Munich, Bayern, Germany

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria.

BiotechnologyGenetics
SeedMay 23, 2023
Amount Raised: $1,292,338
DiogenX

Marseille, Provence-Alpes-Cote d'Azur, France

DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.

BiotechnologyLife Science
Series AMay 10, 2023
Amount Raised: $36,792,809